Here we demonstrate that ZNF224 gene expression is down-regulated both in BCR-ABL positive cell lines and in primary CML samples and is restored after imatinib and second generation tyrosine kinase inhibitors treatment. Here, ZNF224 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.